Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Mescaline/Substance Use Disorders (SUD)

Mescaline for Substance Use Disorders (SUD)

36 papers and 0 clinical trials exploring mescaline as a treatment for substance use disorders (sud).

CompoundPhenethylamine

Mescaline

A naturally occurring phenethylamine psychedelic found in certain cacti, investigated for its role in religious practice and psychiatric research.

Full Mescaline profile
IndicationAmong the world’s largest preventable health burdens

Substance Use Disorders (SUD)

Addiction is one of the oldest hopes for psychedelic medicine, going back to LSD trials for alcoholism in the 1950s. Today psilocybin is the workhorse, with positive trials in alcohol, tobacco and cocaine use disorders, and the cross-substance signal is real. But the picture is mixed rather than settled: a major alcohol trial was null, the studies are small, and almost all of them struggle to keep patients unaware of whether they got the drug. This page is the hub; alcohol, opioid and tobacco use disorders have their own dedicated pages.

Full Substance Use Disorders (SUD) profile

Academic Research

36 papers
Paywallindividual

A qualitative analysis of participant expectations and experiences of psilocybin-assisted psychotherapy for methamphetamine use disorder

Participants in a pilot study of psilocybin‑assisted psychotherapy for methamphetamine use disorder found the intervention acceptable and reported that confronting vividly challenging psychedelic experiences—described as “leaning into the obstacle”—fostered new self‑understandings and shifts in relationships that reduced the salience of methamphetamine. A strong therapeutic alliance, characterised by concentrated attention and intersubjective intimacy, was seen as critical to these positive changes.

Published
December 22, 2025
Journal
Addiction
Authors
Brett, J., Lea, T., Knock, E., Albert, S., Acheson, L., Siefried, K. J., Job, S.
Open Accessindividual

Health-related behavioral changes following the use of psychedelics in naturalistic settings

This cross-sectional study (n=2,510) of US adults with psychedelic experience found that participants retrospectively reported widespread improvements in health behaviours including reduced alcohol (66%) and tobacco (49%) use, better dietary habits (49%), and decreased impulsivity (48-72%), with microdosers and frequent users showing greater positive changes.

Published
August 1, 2025
Journal
Preventative Medicine Reports
Authors
Teixeira, P. J., Jain, R., Penn, A. D., Cole, S. P., Jain, S., Moller, A. C., Amaro, H., Raison, C.
Open Accessmeta

Insights on Psychedelics: A Systematic Review of Therapeutic Effects

This systematic review (s=98) examining psychedelic-catalysed insight found that 86% of studies showed insight was linked to therapeutic improvement, with insight being dose-dependent and significantly higher than placebo in 93% of comparative studies, suggesting insight may be a key mechanism in psychedelic therapy.

Published
March 22, 2025
Journal
Neuroscience and Biobehavioral Reviews
Authors
Kugel, J., Laukkonen, R., Yaden, D. B., Yücel, M., Liknaitzky, P.
Open Accessmeta

Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies

This systematic review (2024) and meta-analysis (s=131) examines the incidence of psychedelic-induced psychosis, focusing on individuals with schizophrenia. It finds an incidence of 0.002% in population studies, 0.2% in UCTs, and 0.6% in RCTs, with 3.8% of UCT participants with schizophrenia developing long-lasting psychotic symptoms. It also reports that 13.1% of those with psychedelic-induced psychosis later developed schizophrenia.

Published
November 27, 2024
Journal
Molecular Psychiatry
Authors
Sabé, M., Sulstarova, A., Glangetas, A., De Pieri, M., Mallet, L., Curtis, L., Richard-Lepouriel, H., Penzenstadler, L., Seragnoli, F., Thorens, G., Zullino, D., Preller, K., Böge, K., Leucht, S., Correll, C. U., Solmi, M., Kaiser, S., Kirschner, M.
Open Accessindividual

Psilocybin-assisted therapy and HIV-related shame

In a pilot clinical trial (N = 12), psilocybin-assisted group therapy produced a large, statistically significant reduction in HIV-related shame from baseline to three-month follow-up. However, two participants experienced a paradoxical worsening of sexual abuse–related shame, highlighting potential risks for trauma-exposed patients.

Published
August 2, 2024
Journal
Scientific Reports
Authors
Mehtani, N. J., Johnson, M. O., Hendricks, P. S., Mitchell, J., Anderson, B. T.
Open Accessindividual

Pharmacological effects of methylone and MDMA in humans

In a randomised, double‑blind, placebo‑controlled crossover trial in 17 experienced psychostimulant users, a single oral dose of methylone (200 mg) produced sympathomimetic effects and stimulant/entactogenic subjective effects similar to MDMA (100 mg) but with a faster onset and shorter duration. These results indicate methylone’s acute pharmacological profile and abuse potential in humans are comparable to those of MDMA.

Published
February 17, 2023
Journal
Frontiers in Pharmacology
Authors
Poyatos, L., Pérez-Mañá, C., Hladun, O., Núñez-Montero, M., De La Rosa, G., Martín, S., Barriocanal, A. M., Carabias, L., Kelmendi, B., Taoussi, O., Busardò, F. P., Fonseca, F., Torrens, M., Pichini, S., Farré, M., Papaseit, E., Lutfy, K., Baumann, M. H.

Clinical Trials

0 trials

No clinical trials have been tagged with both Mescaline and Substance Use Disorders (SUD) yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all Mescaline papers Search all Substance Use Disorders (SUD) trials Full Mescaline profile Full Substance Use Disorders (SUD) profile